Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are the most recently approved class of diabetes drugs. Unlike other agents, SGLT2 inhibitors act on the kidney to promote urinary glucose excretion. SGLT2 inhibitors provide multiple benefits, including decreased HbA(1c), body weight, and blood pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Beitelshees, Amber L., Leslie, Bruce R., Taylor, Simeon I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Perspectives in Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610013/
https://www.ncbi.nlm.nih.gov/pubmed/31109940
http://dx.doi.org/10.2337/dbi18-0006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610013/
https://www.ncbi.nlm.nih.gov/pubmed/31109940
http://dx.doi.org/10.2337/dbi18-0006

Ejemplares similares